Aegis Capital affirms Rosetta Genomics (NASDAQ: ROSG) with a Buy rating and $3.50 price target after ROSG reported Q4/FY15 results earlier Thursday.

Analyst Robert LeBoyer commented, We believe this quarterly report confirms our belief that the company has high-value cancer diagnostic products that can provide revenue growth in FY2016. The company ended the year with cash and equivalent of $13.2 million, not including the $1.6 million in licensing revenues earning in January 2016.

On estimate adjustments: We have raised our FY2016 estimates slightly, in view of the stronger results for FY2015. Our revenue estimate is now $19.1 million for the full year, ahead of the company guidance of over $18 million.

For an analyst ratings summary and ratings history on Rosetta Genomics click here. For more ratings news on Rosetta Genomics click here.